Risk factors and current management in carcinoma of the endometrium. 1986

J T Wharton, and J J Mikuta, and C Mettlin, and G P Murphy, and C J Snyder, and M S Piver, and N Natarajan, and W Donegan

Approximately 3,000 women die each year in the United States of carcinoma of the endometrium. Statistics which have been complied by the American Cancer Society record 39,000 new instances each year. This high cure rate is dependent upon the frequent and correct use of diagnostic techniques and the excellent patient education programs now in use. The results of this study also collaborate the value and cost effectiveness of the patient receiving treatment in community-based comprehensive therapy centers or properly equipped hospitals. In this survey, patients are identified who are at high risk for having carcinoma of the endometrium and prognostic factors which are frequently discovered by careful pretherapy evaluation are discussed. The current therapy methods being used today are presented so that trends are easily detected. The data entered by 546 participating hospitals are not to be used as a guide to therapy, but as a study of the current state of the art in the treatment of this malignant disease.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003276 Contraceptives, Oral Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both. Low-Dose Oral Contraceptive,Oral Contraceptive,Oral Contraceptives,Oral Contraceptives, Low-Dose,Oral Contraceptives, Phasic,Contraceptive, Low-Dose Oral,Contraceptive, Oral,Contraceptives, Low-Dose Oral,Contraceptives, Phasic Oral,Low Dose Oral Contraceptive,Low-Dose Oral Contraceptives,Oral Contraceptive, Low-Dose,Oral Contraceptives, Low Dose,Phasic Oral Contraceptives
D004967 Estrogens Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. Estrogen,Estrogen Effect,Estrogen Effects,Estrogen Receptor Agonists,Estrogenic Agents,Estrogenic Compounds,Estrogenic Effect,Estrogenic Effects,Agents, Estrogenic,Agonists, Estrogen Receptor,Compounds, Estrogenic,Effects, Estrogen,Effects, Estrogenic,Receptor Agonists, Estrogen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age

Related Publications

J T Wharton, and J J Mikuta, and C Mettlin, and G P Murphy, and C J Snyder, and M S Piver, and N Natarajan, and W Donegan
January 1970, La Prensa medica mexicana,
J T Wharton, and J J Mikuta, and C Mettlin, and G P Murphy, and C J Snyder, and M S Piver, and N Natarajan, and W Donegan
May 1987, Revue francaise de gynecologie et d'obstetrique,
J T Wharton, and J J Mikuta, and C Mettlin, and G P Murphy, and C J Snyder, and M S Piver, and N Natarajan, and W Donegan
January 2004, Nursing times,
J T Wharton, and J J Mikuta, and C Mettlin, and G P Murphy, and C J Snyder, and M S Piver, and N Natarajan, and W Donegan
January 1989, Giornale italiano di oncologia,
J T Wharton, and J J Mikuta, and C Mettlin, and G P Murphy, and C J Snyder, and M S Piver, and N Natarajan, and W Donegan
June 1975, R.I. medical journal,
J T Wharton, and J J Mikuta, and C Mettlin, and G P Murphy, and C J Snyder, and M S Piver, and N Natarajan, and W Donegan
February 1987, American journal of clinical oncology,
J T Wharton, and J J Mikuta, and C Mettlin, and G P Murphy, and C J Snyder, and M S Piver, and N Natarajan, and W Donegan
January 1986, CA: a cancer journal for clinicians,
J T Wharton, and J J Mikuta, and C Mettlin, and G P Murphy, and C J Snyder, and M S Piver, and N Natarajan, and W Donegan
February 1958, The Illinois medical journal,
J T Wharton, and J J Mikuta, and C Mettlin, and G P Murphy, and C J Snyder, and M S Piver, and N Natarajan, and W Donegan
May 1978, Journal of the National Medical Association,
J T Wharton, and J J Mikuta, and C Mettlin, and G P Murphy, and C J Snyder, and M S Piver, and N Natarajan, and W Donegan
April 1986, The British journal of clinical practice,
Copied contents to your clipboard!